Extract
We read with great interest the article published in the European Respiratory Journal by Hambly et al. [1] on the prevalence and characteristics of progressive fibrosing interstitial lung disease (ILD) in patients diagnosed with fibrotic ILD. The study showed that half (50.1%) of 2746 patients with fibrotic ILD develop progressive fibrosing ILD within 24 months and that the prevalence of progressive fibrosing ILD is 59% in idiopathic pulmonary fibrosis, 58% in hypersensitivity pneumonitis, 51% in unclassifiable ILD and 45% in connective tissue disease-associated ILD [1].
Abstract
Awareness of the risk factors for disease progression in hypersensitivity pneumonitis will be very useful as a guide to deciding therapeutic approaches for this devastating disease in real world clinical practice https://bit.ly/3xG4B16
Footnotes
Author contributions: Approval and writing the correspondence draft: H. Fujimoto, T. Yasuma, C.N. D'Alessandro-Gabazza, E.C. Gabazza, O. Hataji and T. Kobayashi.
Conflict of interest: H. Fujimoto reports grants from Chugai, Pfizer, ONO, TAIHO, Boehringer Ingelheim and Eli Lilly, outside the submitted work. T. Yasuma reports grants from Shionogi, outside the submitted work. C.N. D'Alessandro-Gabazza reports grants from Shionogi Pharmaceutical Inc., Astellas Pharmaceuticals Inc. and Asahi Kassei, outside the submitted work. E.C. Gabazza reports grants from Shionogi Pharmaceutical Inc., Astellas Pharmaceuticals Inc. and Asahi Kassei, outside the submitted work. O. Hataji reports grants from Janssen Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Fukuda Denshi and Kyorin Pharmaceutical, grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merk Sharp & Dohme (MSD), Novartis, Ono Pharmaceutical, Sanofi Pharmaceutical and Takeda Pharmaceutical, personal fees from Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Chemiphar and Taiho Pharmaceutical, outside the submitted work. T. Kobayashi reports grants and personal fees from Chugai, Pfizer, ONO, Boehringer Ingelheim and Eli Lilly, grants from TAIHO, outside the submitted work.
- Received August 31, 2021.
- Accepted September 15, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
